Richard Hayes
Editor-in-Chief, PeptideMark
Richard founded PeptideMark to create an independent, evidence-based peptide reference free from vendor influence. He oversees editorial standards, content strategy, and ensures every claim on the site is properly cited and evidence-rated. His work focuses on translating complex pharmacological research into accessible, well-sourced educational content.
Areas of Focus
Peptide pharmacologyEvidence-based health contentFDA & regulatory analysisClinical trial interpretationScientific publishing standardsWADA prohibited substances
Compound Profiles (20)
Evidence-rated compound profiles reviewed and approved by Richard.
BPC-157·healing recoverySemaglutide·weight lossTirzepatide·weight lossTB-500·healing recoveryCJC-1295·growth hormoneIpamorelin·growth hormoneGHK-Cu·skin hairPT-141·sexual healthSermorelin·growth hormoneTesamorelin·growth hormone
View all 20 compounds Guides (9)
- What Are Peptides? A Science-Based Introduction
- Peptides for Weight Loss: What the Research Shows
- FDA Regulation of Peptides: What You Need to Know
- Understanding Our Evidence Ratings
- Growth Hormone Secretagogues Explained
- GLP-1 Receptor Agonists: From Semaglutide to Retatrutide
- How to Reconstitute Peptides: Step-by-Step
- Peptide Storage & Handling Best Practices
- How to Read Peptide Research Papers
Educational Articles (23)
- Peptide Stacking: What the Research Actually Shows
- Oral vs Injectable Peptides: Bioavailability & Delivery Guide
- Peptide Half-Lives Explained: Why Duration Matters
- Peptide Therapy Cost Guide 2026: What to Expect
- Peptides vs SARMs vs Steroids: Key Differences Explained
- The Complete History of the FDA Peptide Crackdown
- Compounding Pharmacy Regulation: What Changed and What It Means for Peptides
- The GLP-1 Market: How Semaglutide and Tirzepatide Created a $50B Industry
- Peptide Research Funding: Who Is Paying for Clinical Trials?
- WADA, Sports, and Peptides: The Complete Anti-Doping Guide
- Telehealth Peptide Prescriptions: How Online Clinics Are Changing Access
- Insurance Coverage for Peptide Therapy: A State-by-State Analysis
- How Peptides Are Manufactured: From Lab Synthesis to Clinical Grade
- International Peptide Regulation: US vs EU vs Australia vs Russia
- The Science of Peptide Stability: Storage, Reconstitution, and Degradation
- Are Peptides Safe? Side Effects, Risks & What the Evidence Shows
- Best Peptides for Muscle Growth & Recovery: What the Research Shows
- Best Peptides for Anti-Aging & Longevity: What the Evidence Actually Shows
- Peptides for Hair Growth & Hair Loss: What the Research Actually Shows
- Peptides for Gut Health & IBS: Evidence Review 2026
- Peptides for Sleep & Recovery: Clinical Evidence 2026
- Peptides for Cognitive Function & Brain Health: Evidence Review 2026
- Anti-Inflammatory Peptides: Evidence-Based Review 2026
News & Analysis (65)
- RFK Jr. Announces 14 Peptides Moving Back to Category 1: What It Means
- Ozempic Side Effects: What 5 Years of Real-World Data Actually Shows
- Oral Wegovy Pill Gets FDA Approval: What You Need to Know
- Retatrutide Phase 3: Triple Agonist Delivers 71 lbs Average Weight Loss
- Semaglutide Could Cost $3/Month: Patent Expiry and Generic Timeline
- Tirzepatide vs. Semaglutide: What the Head-to-Head Trials Show
- FDA Category 2 Peptide Ban: The Complete Guide
- How to Prevent Muscle Loss on Ozempic and Other GLP-1 Drugs
- "Ozempic Face" Explained: What Causes It and What Helps
- Peptide Compounding in 2026: What Patients Need to Know
- GLP-1 Drugs and Cancer Risk: What the Research Actually Shows
- 2026 Weight Loss Drug Pipeline: What Comes After Ozempic
- Tirzepatide 3-Year Data: Weight Loss Sustained at 22.9%
- Eli Lilly Warns of Counterfeit Tirzepatide: How to Stay Safe
- How GLP-1 Drugs Are Cutting America's Grocery Bills